Pro-Dex Stock (NASDAQ:PDEX), Trade Ideas

Pro-Dex

Pro-Dex Inc is engaged in designing, developing, and manufacturing powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. In addition, the company provides engineering consulting and placement services, as well as quality and regulatory consulting services. Most of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

AADI

APLT

ASPS

ATER

AVTE

BBIG

BILL

BLCT

BLIN

BLUW

BTBT

CEMI

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNTB

DATS

DOMO

EFTR

ELYM

GAMB

HIBB

HUDI

HUMA

IKNX

LXRX

MDIA

MKTY

MMAT

MRIN

NLTX

NSPR

NURO

OLLI

PDEX

PRPO

PTON

PXLW

REKR

RNXT

RPHM

RPID

SAVA

SBET

SGOC

SPRT

SYTA

VECT

VLON

WDAY

Gainers


	Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.


60 Biggest Movers From Friday

ADTN

AMTX

ASRT

ATOS

AUPH

BIVI

CARG

CCXI

CGAU

CLNN

CTHR

CVAC

CYCN

DDOG

EARS

EMKR

EPZM

EXPE

FARM

FNKO

FROG

FSTX

GDEN

HMPT

IBIO

LEDS

LMFA

MITO

MOSY

NGVC

NKLA

ORGS

ORPH

PHIO

PIXY

PUBM

QRTEA

REPH

ROKU

SHAK

TLRY

TRHC

TVTX

UEIC

WTRH

YMAB

YTEN

Gainers


	InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.


70 Biggest Movers From Friday

Earnings

Eurozone

Commodities

Global

Intraday Update

Toward the end of trading Friday, the Dow traded up 0.62% to 34,761.24 while the NASDAQ rose 0.95% to 13,762.12. The S&amp;P also rose, gaining 0.74% to 4,232.81.

Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop

Pro-Dex Inc

Polkadex

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.35 by 60 percent. This is a 41.67 percent decrease over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $12.59 million which beat the analyst consensus estimate of $11.50 million by 9.46 percent. This is a 11.58 percent increase over sales of $11.28 million the same period last year.

Earnings Beats

Earnings Misses

Pro-Dex Q2 EPS $0.14, Sales $12.59M Beat $11.50M Estimate

<h3>Gainers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares rose 10.5% to $0.66 during Thursday's after-market session. The market value of their outstanding shares is at $18.2 million. </li>
<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) stock increased by 9.58% to $4.0. The company's market cap stands at $65.5 million. The company's, Q4 earnings came out today. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock moved upwards by 8.49% to $2.17. The market value of their outstanding shares is at $106.4 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares moved upwards by 6.86% to $1.09. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) stock rose 6.2% to $0.51. The company's market cap stands at $17.3 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares moved upwards by 4.99% to $0.18. The company's market cap stands at $32.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) stock fell 42.1% to $2.17 during Thursday's after-market session. The market value of their outstanding shares is at $64.9 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock declined by 29.76% to $0.38. The company's market cap stands at $19.0 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock fell 13.82% to $4.18. The company's market cap stands at $26.8 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock fell 10.56% to $0.14. The market value of their outstanding shares is at $1.2 million. </li>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) stock declined by 8.96% to $0.11. The market value of their outstanding shares is at $5.0 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock decreased by 8.28% to $19.5. The company's market cap stands at $69.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

BTAI

COEP

CRVS

NSTG

RNLX

SINT

SNES

SRTS

SYRA

12 Health Care Stocks Moving In Thursday's After-Market Session

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.32 by 153.13 percent. This is a 158.62 percent decrease over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $11.94 million which beat the analyst consensus estimate of $11.20 million by 6.59 percent. This is a 7.68 percent increase over sales of $11.09 million the same period last year.

Pro-Dex Q1 EPS $(0.17) May Not Compare To $0.32 Estimate, Sales $11.94M Beat $11.20M Estimate

WIIM

Pro-Dex shares are trading higher after the company reported better-than-expected Q4 EPS results.

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.33 by 27.27 percent. This is a 10.53 percent increase over earnings of $0.38 per share from the same period last year.

Pro-Dex Q4 EPS $0.42 Beats $0.33 Estimate

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.26 by 38.46 percent. This is a 200 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $13.08 million which beat the analyst consensus estimate of $9.80 million by 33.46 percent. This is a 41.17 percent increase over sales of $9.27 million the same period last year.

Pro-Dex Q3 EPS $0.36 Beats $0.26 Estimate, Sales $13.08M Beat $9.80M Estimate

<a href="https://pro.benzinga.com/?utm_source=insights">According to Benzinga Pro data</a> Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) posted a 18.31% decrease in earnings from Q1. Sales, however, increased by 1.76% over the previous quarter to $11.28 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Pro-Dex is not utilizing their capital as effectively as possible. In Q1, Pro-Dex earned $1.08 million and total sales reached $11.09 million. 
<h3>What Is Return On Capital Employed?</h3>
Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Pro-Dex posted an ROCE of 0.04%.
It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future. 
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Pro-Dex is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth. 
For Pro-Dex, the positive return on capital employed ratio of 0.04% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
<h3>Analyst Predictions</h3>
Pro-Dex reported Q2 earnings per share at $0.24/share, which did not meet analyst predictions of $0.29/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Pro-Dex's Return On Capital Employed Overview

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.29 by 17.24 percent. This is a 4 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $11.28 million which beat the analyst consensus estimate of $10.40 million by 8.48 percent. This is a 10.90 percent increase over sales of $10.17 million the same period last year.

Pro-Dex Q2 EPS $0.24 Misses $0.29 Estimate, Sales $11.28M Beat $10.40M Estimate

<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data,</a> Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) posted Q1 earnings of $1.08 million, an increase from Q4 of 23.42%. Sales dropped to $11.09 million, a 12.11% decrease between quarters. In Q4, Pro-Dex earned $1.41 million, and total sales reached $12.62 million. 
<h3>Why Is ROIC Significant?</h3>
Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q1, Pro-Dex posted an ROIC of 2.52%.
Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. 
ROIC is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROIC shows Pro-Dex is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of invested capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth. 
For Pro-Dex, the positive return on invested capital ratio of 2.52% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.
<h3>Analyst Predictions</h3>
Pro-Dex reported Q1 earnings per share at $0.29/share, which did not meet analyst predictions of $0.33/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Pro-Dex Earnings Perspective: Return On Invested Capital

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.29 per share. This is a 3.57 percent increase over earnings of $0.28 per share from the same period last year.

Pro-Dex Q1 EPS $0.29 Up From $0.28 YoY

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.38 per share. This is a 90 percent increase over earnings of $0.20 per share from the same period last year. The company reported $12.62 million in sales this quarter. This is a 33.70 percent increase over sales of $9.44 million the same period last year.

Pro-Dex Q4 EPS $0.38 Up From $0.20 YoY, Sales $12.62M Up From $9.44M YoY

Pro-Dex shares are trading lower after the company reported Q3 EPS and sales results were lower year over year.

Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) reported quarterly earnings of $0.12 per share. This is a 77.78 percent decrease over earnings of $0.54 per share from the same period last year. The company reported $9.30 million in sales this quarter. This is a 20.78 percent decrease over sales of $11.74 million the same period last year.

Pro-Dex Q3 EPS $0.12 Down From $0.54 YoY, Sales $9.30M Down From $11.74M YoY

Options

ACLX

ADAG

AMWL

ANIK

AOUT

ASXC

ATHM

AVLR

AXDX

BABA

BAND

BBLN

BEKE

BEST

BIDU

BILI

BIRD

BTNB

BYND

BZUN

CAAS

CMCM

COCO

COMM

CRDL

CRTO

CTRN

DAKT

DIDI

DOCU

DOYU

ECOM

New Oriental Education & Technology Group

Eaton Vance California Municipal Bond Fund

First Trust/Aberdeen Emerging Opportunity Fund

FMAC

FTCH

FTRP

FUTU

GAIA

GAME

GOED

GSMG

HAPP

Stocks That Hit 52-Week Lows On Friday